| Zhang, Qingyuan |
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
NCT06680921: A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
NCT05257395: A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer |
|
|
| Not yet recruiting | 3 | 372 | RoW | XZP-3287+ Letrozole/Anastrozole, Placebo + Letrozole/Anastrozole | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Breast Cancer | 12/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT04165993: Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer |
|
|
| Active, not recruiting | 2 | 68 | RoW | Concurrent chemotherapy and KN026, docetaxol, KN026 monotherapy, KN026, KN026 combination, KN046 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Metastatic Breast Cancer | 05/21 | 12/25 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
TQB2102-II-01, NCT06198751: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer |
|
|
| Recruiting | 2 | 104 | RoW | 6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/25 | 02/26 | | |
NCT06354114: A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 |
|
|
| Not yet recruiting | 2 | 80 | RoW | SYHX2011 | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Breast Cancer | 10/24 | 12/26 | | |
HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
|
|
| Active, not recruiting | 2 | 131 | RoW | HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 05/24 | 06/25 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT06433362: CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 115 | RoW | CMOEP | Tianjin Medical University Cancer Institute and Hospital | Peripheral T Cell Lymphoma | 06/25 | 06/26 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 42 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 06/26 | 06/28 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
NCT06202261: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 154 | RoW | TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets, Vinorelbine tartrate injection, Eribulin mesylate injection, gemcitabine hydrochloride for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies | 12/26 | 10/27 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 220 | RoW | Dose Escalation, Dose Expansion1, Dose Expansion2, phase II | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Advanced Malignant Solid Tumors | 05/28 | 12/28 | | |
NCT06679036: A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 300 | RoW | HRS-2189, Fluvustat, HRS-8080, HRS-6209, HRS-1358 | Shandong Suncadia Medicine Co., Ltd. | Advanced Unresectable or Metastatic Breast Cancer | 10/26 | 12/26 | | |
NCT04980690: Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 228 | RoW | IBC0966 | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Malignant Tumors | 12/24 | 12/25 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 60 | RoW | PM8002, nab-paclitaxel | Biotheus Inc. | TNBC | 10/26 | 10/26 | | |
NCT04871347: The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor |
|
|
| Not yet recruiting | 1a/1b | 58 | RoW | TWP-101, Sytalizumab Injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Solid Tumor | 06/23 | 12/23 | | |
NCT03374007: Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma |
|
|
| Recruiting | 1 | 72 | RoW | Geptanolimab Injection 1mg/kg, Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection, Geptanolimab Injection 3mg/kg, Geptanolimab Injection 10mg/kg, Geptanolimab Injection 1mg/kg, q2w*6, Geptanolimab Injection 3mg/kg, q2w*6, Geptanolimab Injection 10mg/kg, , q2w*6, Geptanolimab Injection 280mg, q3w, Geptanolimab Injection 3mg/kg, q2w | Genor Biopharma Co., Ltd. | Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma, Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma | 06/22 | 08/22 | | |
TWP-102-11, NCT05024305: Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies. |
|
|
| Recruiting | 1 | 81 | RoW | TWP-102 injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Malignancies | 12/22 | 06/23 | | |
NCT05103826: A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer |
|
|
| Terminated | 1 | 3 | RoW | SHR6390、Famitinib | Jiangsu HengRui Medicine Co., Ltd. | ER+ / HER2- Advanced Breast Cancer | 06/23 | 06/23 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
BL-M17D1-101, NCT06503783: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 08/26 | 08/26 | | |
NCT06718634: A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies |
|
|
| Not yet recruiting | 1 | 22 | RoW | BL-M08D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Relapsed or Refractory Lymphoid Malignancies | 12/26 | 06/27 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT05851092: Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 60 | RoW | HRS-2189 Tablets | Shandong Suncadia Medicine Co., Ltd. | Advanced Malignant Tumor | 12/25 | 12/25 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Guo, Jinmin |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
